Anavex Life Sciences (US:AVXL) Newsfilter·2025-04-23 11:30Core Viewpoint - Anavex Life Sciences Corp. has appointed Professor Dr. Audrey Gabelle to its Scientific Advisory Board, enhancing its expertise in Alzheimer's disease and related disorders, particularly in predictive and personalized medicine [1][6]. Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and Rett syndrome [7]. - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [7]. Appointment of Professor Dr. Audrey Gabelle - Professor Dr. Gabelle is a specialist in predictive, personalized medicine and digital health, with over 10 years of experience in clinical trials and managing memory centers in France [2][3]. - She has a strong publication record with over 200 peer-reviewed scientific papers and has been involved in significant research projects at both European and global levels [3][4]. - Dr. Gabelle's expertise includes the creation of a NeuroCognition biobank with over 35,000 samples, focusing on risk stratification and preventive strategies for neurodegenerative diseases [4]. Focus Areas and Contributions - Dr. Gabelle's recent work emphasizes real-world evidence, digital health strategies, and artificial intelligence, which she honed through training at prestigious institutions [5]. - She expressed enthusiasm about joining Anavex, highlighting the unmet medical need for Alzheimer's treatments and the potential impact of blarcamesine on patient care and healthcare equity [6]. - Anavex's CEO, Christopher U Missling, acknowledged Dr. Gabelle's broad expertise in Alzheimer's disease and digital health, anticipating her active contributions to advancing blarcamesine [6].